Biogennix Reports Record Sales Month for July 2019

IRVINE, Calif.–(BUSINESS WIRE)–Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone grafting products used for bone fusion procedures, announced today that its July performance was the best in the company’s history.

“The momentum we have developed over the year really culminated into our best sales performance to date,” said Chris MacDuff, Biogennix’s CEO. “With a dedicated focus by our regional sales managers, increased marketing initiatives and, most importantly, our distributor partner efforts, we have been able to significantly expand our sales. Our Morpheus™ product is fast becoming the standard of effectiveness and ease of use in the bone graft products space and there is yet more to come from Biogennix very soon.”

MacDuff also noted that to accommodate the year’s growth and increasing demand for its products, Biogennix is in the process of increasing its manufacturing capabilities, further expanding its sales team, and boosting its R&D capabilities.

The majority of Biogennix’s steady growth is attributed to increases in sales of the company’s novel bone grafting products, Morpheus and osteoSPAN™, both of which are resorbable, osteoconductive scaffolds ideally suited for bone regeneration. The Morpheus product is a moldable version of osteoSPAN, which combines the granules with an organic binder, providing optimal handling characteristics for surgeons.